Our Journey

We're making progress using AI to make better medicines, faster.

The Atomwise
Story

While at the University of Toronto, we saw early on how machine learning and convolutional neural networks could be applied for image recognition. We founded Atomwise to prove the concept that the same technology could be applied to drug discovery by performing computational screens to find molecules worth testing in the lab.

Building on this early successs we've expanded the robustness of our models through early collaborations with academic researchers and biopharma partnerships. AtomNet® technology now scales to screening billions of molecules for multiple projects simultaneously. We now use AI as a robust engine for drug discovery resulting in joint ventures, jointly held assets, and our wholly owned pipeline to address previously undrugged diseases.

2012

Proof of Concept

Invented the first application of CNN technology for drug discovery.

Technology R&D
Company Milestone
Technology R&D
2017

Early Technology Partnerships

Matured the AtomNet® technology platform by tackling more challenging targets with biopharma and AIMS academic partners.

AIMS Program
Biopharma Partnership
Company Milestone
Biopharma Partnership
AIMS Program
Technology R&D
2020

Pivotal Year

Massively scaled the AtomNet® platform and grew the company to become the leading AI drug discovery engine in biopharma.

Biopharma Partnership
AIMS Program
Company Milestone
Technology R&D
Biopharma Partnership
2021

Robust Discovery Engine

Leveraging our drug discovery engine to deliver better medicines faster.

Become an Atom

Learn more about life at Atomwise or browse our current openings.

Life at Atomwise Current Openings